Аннотация
Главной мишенью новой коронавирусной инфекции (COVID19), распространяемой вирусом SARS-CoV-2, является дыхательная система. Инфекция SARS-CoV-2 может вызывать поражение почек, а тяжелая почечная дисфункция чаще встречается у пациентов с хроническими сопутствующими коморбидными/мультиморбидными заболеваниями, особенно у пациентов с хроническим заболеванием почек. Проведен поиск литературы о связи основных заболеваний (патологических состояний) почек и мочевых путей с новой коронавирусной инфекцией COVID-19 в электронных поисковых системах PubMed, Scopus, eLIBRARY. Найденные литературные источники свидетельствуют, что новая коронавирусная инфекция COVID-19 безусловно оказывает специфическое влияние как на мочевыделительную систему в целом, так и на отдельные заболевания почек и мочевых путей в частности.
Ключевые слова: новая коронавирусная инфекция (COVID-19), острое повреждение почек, острая почечная недостаточность, хроническая болезнь почек, хроническая почечная недостаточность, цистит, симптомы нижних мочевых путей, пиелонефрит, мочекаменная болезнь, гломерулонефрит, нефротоксичность лекарственных препаратов.
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
Ключевые слова: новая коронавирусная инфекция (COVID-19), острое повреждение почек, острая почечная недостаточность, хроническая болезнь почек, хроническая почечная недостаточность, цистит, симптомы нижних мочевых путей, пиелонефрит, мочекаменная болезнь, гломерулонефрит, нефротоксичность лекарственных препаратов.
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
Об авторе
Д.И. Трухан
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
dmitry_trukhan@mail.ru
Список литературы
1. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России (15-я версия от 22.02.2022). М., 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/ 000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii (15-ia versiia ot 22.02.2022). Moscow, 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
2. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9 (1):727–32. DOI: 10.1080/22221751.2020.1746199
3. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14 (2): 185–92. DOI: 10.1007/ s11684-020-0754-0
4. Wang M, Xiong H, Chen H et al. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis (Basel). 2021 Mar; 7 (2): 100–10. DOI: 10.1159/000512683
5. Томилина Н.А., Фролова Н.Ф., Артюхина Л.Ю. и др. COVID-19: связь с патологией почек. Обзор литературы. Нефрология и диализ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id= 46215426
[Tomilina N.A., Frolova N.F., Artiukhina L.Iu. et al. COVID-19: sviaz' s patologiei pochek. Obzor literatury. Nefrologiia i dializ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id=46215426 (in Rus-sian).]
6. Павлов В.Н., Тарасенко А.И., Папоян А.О. и др. Острое повреждение почек в патогенезе коронавирусной инфекции. Урология. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119
[Pavlov V.N., Tarasenko A.I., Papoian A.O. et al. Ostroe povrezhdenie pochek v patogeneze koronavirusnoi infektsii. Urologiia. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119 (in Russian).]
7. Демяшкин Г.А., Мингазов А.М., Каприна Е.А. и др. Молекулярно-генетические изменения ткани почек пациентов с COVID-19. Исследования и практика в медицине. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4
[Demiashkin G.A., Mingazov A.M., Kaprina E.A. et al. Molekuliarno-geneticheskie izmeneniia tkani pochek patsientov s COVID-19. Issledovaniia i praktika v meditsine. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4 (in Russian).]
8. Ouyang L, Gong Y, Zhu Y, Gong J. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am J Emerg Med 2021; 43: 149–57. DOI: 10.1016/j.ajem.2020 08.089
9. Острое повреждение почек (ОПП). Клинические рекомендации. М., 2020. https://rusnephrology.org/wp-content/uploads/2020/12/ AKI_final.pdf
[Ostroe povrezhdenie pochek (OPP). Klinicheskie rekomendatsii. Moscow, 2020. https://rusnephrology.org/wp-content/uploads/ 2020/12/AKI_final.pdf (in Russian).]
10. Pecly IMD, Azevedo RB, Muxfeldt ES et al. A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. J Bras Nefrol 2021; 43 (4): 551–71. DOI: 10.1590/2175-8239-JBN-2020-0204
11. Yang XH, Sun RH, Chen DC. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Zhonghua Yi Xue Za Zhi 2020; 100 (16): 1205–8. DOI: 10.3760/cma.j.cn112137-20200229-00520
12. Ng JH, Bijol V, Sparks MA et al. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis 2020; 27 (5): 365–76. DOI: 10.1053/j.ackd.2020.09.003
13. Menon T, Sharma R, Kataria S et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cureus 2021; 13 (3): e13894. DOI: 10.7759/cureus.13894
14. Chan KW, Yu KY, Lee PW et al. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021; 8: 678200. DOI: 10.3389/fmed.2021.678200
15. Oliveira CB, Lima CAD, Vajgel G et al. High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. J Clin Pathol 2021; 74 (12): 796–803. DOI: 10.1136/jclinpath-2020-207023
16. Alenezi FK, Almeshari MA, Mahida R et al. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis. Ren Fail 2021; 43 (1): 1621–33. DOI: 10.1080/0886022X.2021.2011747
17. Raina R, Mahajan ZA, Vasistha P et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif 2021: 1–14. DOI: 10.1159/000514940
18. Santos RPD, Lordani TVA, Peres LAB, Carvalho ARDS. Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.09.002
19. Cai X, Wu G, Zhang J, Yang L. Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8: 719472. DOI: 10.3389/fmed.2021.719472
20. Чеботарева Н.В., Бернс С.А., Мясников А.Л. и др. Частота, факторы риска и прогностическое значение острого повреждения почек у госпитализированных больных c COVID-19: ретроспективное когортное исследование. Клиническая фармакология и терапия. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35
[Chebotareva N.V., Berns S.A., Miasnikov A.L. et al. Chastota, faktory riska i prognosticheskoe znachenie ostrogo povrezhdeniia pochek u gospitalizirovannykh bol'nykh c COVID-19: retrospektivnoe kogortnoe issledovanie. Klinicheskaia farmakologiia i terapiia. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35 (in Russian).]
21. Chan VW, Chiu PK, Yee CH et al. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol 2021; 39 (9): 3127–38. DOI: 10.1007/s00345-020-03246-4
22. Громова Г.Г., Верижникова Л.Н., Жбанова Н.В. и др. Повреждение почек при новой коронавирусной инфекции COVID-19. Клиническая нефрология. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22
[Gromova G.G., Verizhnikova L.N., Zhbanova N.V. et al. Povrezhdenie pochek pri novoi koronavirusnoi infektsii COVID-19. Klinicheskaia nefrologiia. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22 (in Russian).]
23. Cai R, Zhang J, Zhu Y et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol 2021; 53 (8): 1623–9. DOI: 10.1007/s11255-020-02740-3
24. Menon T, Gandhi SAQ, Tariq W et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. Cureus 2021; 13 (4): e14279. DOI: 10.7759/cureus.14279
25. Lin YC, Lai TS, Lin SL et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021; 12: 2040622321998860. DOI: 10.1177/2040622321998860
26. Chung EYM, Palmer SC, Natale P et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2021; 78 (6): 804–15. DOI: 10.1053/j.ajkd. 2021.07.003
27. Singh J, Malik P, Patel N et al. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med 2022; 22 (1): 125–35. DOI: 10.1007/s10238-021-00715-x
28. Nopsopon T, Kittrakulrat J, Takkavatakarn K et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis. PLoS Negl Trop Dis 2021; 15 (6): e0009156. DOI: 10.1371/journal.pntd.0009156
29. Wang F, Ao G, Wang Y et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail 2021; 43 (1): 1394–407. DOI: 10.1080/0886022X. 2021.1986408
30. Сивков А.В., Корякин А.В., Синягин А.А. и др. Мочеполовая система и COVID-19: некоторые аспекты. Экспериментальная и клиническая урология. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23
[Sivkov A.V., Koriakin A.V., Siniagin A.A. et al. Mochepolovaia sistema i COVID-19: nekotorye aspekty. Eksperimental'naia i klinicheskaia urologiia. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23 (in Russian).]
31. Heldwein FL, Loeb S, Wroclawski ML et al. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus 2020; 6 (5): 1070–85. DOI: 10.1016/j.euf.2020.05.020
32. Лаухтина Е.А., Шпикина А.Д., Тараткин М.С. и др. Обзор рекомендаций европейской ассоциации урологов по ведению урологических пациентов в период пандемии COVID-19. Вопросы урологии и андрологии. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59
[Laukhtina E.A., Shpikina A.D., Taratkin M.S. et al. Obzor rekomendatsii evropeiskoi assotsiatsii urologov po vedeniiu urologicheskikh patsientov v period pandemii COVID-19. Voprosy urologii i andrologii. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59 (in Russian).]
33. Малхасян В.А., Касян Г.Р., Ходырева Л.А. и др. Оказание стационарной помощи пациентам урологического профиля в условиях пандемии коронавирусной инфекции COVID-19. Экспериментальная и клиническая урология. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11
[Malkhasian V.A., Kasian G.R., Khodyreva L.A. et al. Okazanie statsionarnoi pomoshchi patsientam urologicheskogo profilia v usloviiakh pandemii koronavirusnoi infektsii COVID-19. Eksperimental'naia i klinicheskaia urologiia. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11 (in Russian).]
34. Mumm JN, Osterman A, Ruzicka M et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? Eur Urol 2020; 78 (4): 624–8. DOI: 10.1016/j.eururo.2020.05.013
35. Lamb LE, Dhar N, Timar R et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses 2020; 145: 110375. DOI: 10.1016/j.mehy. 2020.110375
36. Dhar N, Dhar S, Timar R et al. De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. J Clin Med Res 2020; 12 (10): 681–2. DOI: 10.14740/jocmr4294
37. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных синдромов и симптомов при заболеваниях почек и мочевых путей. М.: Практическая медицина, 2019. https://www. elibrary.ru/item.asp?id=47503998
[Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh sindromov i simptomov pri zabolevaniiakh pochek i mochevykh putei. Moscow: Prakticheskaia meditsina, 2019. https://www.elibrary. ru/item.asp?id=47503998 (in Russian).]
38. Трухан Д.И., Юренев Г.Л., Макушин Д.Г., Чусова Н.А. Симптомы нижних мочевых путей: дифференциальный диагноз на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801
[Trukhan D.I., Iurenev G.L., Makushin D.G., Chusova N.A. Simptomy nizhnikh mochevykh putei: differentsial'nyi diagnoz na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Spravochnik poliklinicheskogo vracha. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801 (in Russian).]
39. Kaya Y, Kaya C, Kartal T et al. Could LUTS be early symptoms of COVID-19. Int J Clin Pract 2021; 75 (3): e13850. DOI: 10.1111/ ijcp.13850
40. Bernikov AN, Kupriyanov AA, Stroganov RV et al. Lower urinary tract symptoms and COVID-19. Urologiia 2021; 5: 78–83. https://pubmed.ncbi.nlm.nih.gov/35165599/
41. Lamb LE, Timar R, Wills M et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephrol 2022; 54 (1): 17–21. DOI: 10.1007/s11255-021-03030-2
42. Pourfridoni M, Pajokh M, Seyedi F. Bladder and bowel incontinence in COVID-19. J Med Virol 2021; 93 (5): 2609–10. DOI: 10.1002/ jmv.26849
43. Araujo MP, Brito LGO, Pochini AC et al. Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19 Quarantine and its Relationship with Training Level: An Observational Study. Rev Bras Ginecol Obstet 2021; 43 (11): 847–52. DOI: 10.1055/s-0041-1739463
44. Борисов В.В. Опасности COVID-нейроинфекции и ее урологических осложнений, возможные пути преодоления (клиническая лекция). Клинический разбор в общей медицине. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078
[Borisov V.V. Opasnosti COVID-neiroinfektsii i ee urologicheskikh oslozhnenii, vozmozhnye puti preodoleniia (klinicheskaia lektsiia). Klinicheskii razbor v obshchei meditsine. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078 (in Russian).]
45. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103
[Trukhan D.I., Chuianova Iu.S., Makushin D.G. Problema nederzhaniia mochi skvoz' prizmu komorbidnosti. Klinicheskii razbor v obshchei meditsine. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103 (in Russian).]
46. Silva AB, Freschi G, Carrera RV et al. COVID-19 pandemic impact on clinical outcomes of patients with obstructive pyelonephritis. Int Urol Nephrol 2021; 53 (4): 627–33. DOI: 10.1007/s11255-020-02708-3
47. Borgmann H, Struck JP, Mattigk A et al. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Urol Int 2021; 105 (3–4): 199–205. DOI: 10.1159/000513458
48. Krol BC, Hemal AK, Fenu EM et al. A rare case of emphysematous pyelonephritis caused by Candida parapsilosis and Finegoldia magna complicated by medical care avoidance. CEN Case Rep 2021; 10 (1): 111–4. DOI: 10.1007/s13730-020-00531-4
49. Cao BL, Brewer O, Cross AR. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep 2022; 15 (2): e245779. DOI: 10.1136/bcr-2021-245779
50. Djafari AA, Hojjati SA, Rahnama H et al. First report of concurrent mixed germs induced destructive emphysematous pyelonephritis and emphysematous endophthalmitis in the patient with COVID-19. Urol Case Rep 2022; 40: 101908. DOI: 10.1016/j.eucr.2021.101908
51. Boukhannous I, El Moudane A, Chennoufi M et al. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Case Rep Infect Dis 2021; 2021: 3115644. DOI: 10.1155/2021/3115644
52. Castellani D, Ragonese M, Di Rosa M et al. An Italian multicenter analysis of emergency admissions and treatment of upper tract urolithiasis during the lockdown and reopening phases of the COVID-19 pandemic: Are we ready for a second wave of the outbreak? Int J Urol 2021; 28 (9): 950–4. DOI: 10.1111/iju.14612
53. Nourian A, Uppaluri C, Chen M et al. Comparison of Management and Outcomes of Symptomatic Urolithiasis during the COVID-19 Pandemic to a Comparative Cohort. Urology 2022: S0090-4295(22) 00064-4. DOI: 10.1016/j.urology.2022.01.019
54. Anderson S, McNicholas D, Murphy C et al. The impact of COVID-19 on acute urinary stone presentations: a single-centre experience. Ir J Med Sci 2022; 191 (1): 45–9. DOI: 10.1007/s11845-021-02562-x
55. Abdel Raheem A, Alowidah I, Soliman M, et al. Urolithiasis treatment options during COVID-19 pandemic: review of current recommendations and triage systems. Afr J Urol 2020; 26 (1): 75. DOI: 10.1186/s12301-020-00085-y
56. Cepeda M, Budía A, Pérez-Fentes D et al. Strategies and recommendations for urolithiasis treatment and follow-up in COVID-19 pandemia. Arch Esp Urol 2020; 73 (5): 438–46. https://pubmed. ncbi.nlm.nih.gov/32538815/
57. Heijkoop B, Galiabovitch E, York N, Webb D. Consensus of multiple national guidelines: agreed strategies for initial stone management during COVID-19. World J Urol 2021; 39 (9): 3161–74. DOI: 10.1007/ s00345-020-03491-7
58. Scotland K, Tailly T, Chew BH et al. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol 2022. DOI: 10.1089/end.2021.0477
59. Demirdogen SO, Cinislioglu AE, Cinislioglu N et al. Treatment management of COVID-19 positive patients with renal colic secondary to distal ureteral stone. Int J Clin Pract 2021; 75 (5): e13976. DOI: 10.1111/ijcp.13976
60. Moran SM, Barbour S, Dipchand C et al.; CSN COVID-19 Rapid Response Team. Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis 2020; 7: 2054358120968955. DOI: 10.1177/205435 8120968955
61. May RM, Cassol C, Hannoudi A et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021; 100 (6): 1303–15. DOI: 10.1016/j.kint.2021.07.015
62. Waldman M, Soler MJ, García-Carro C et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int 2021; 99 (1): 227–37. DOI: 10.1016/j.kint.2020.10.032
63. Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review. Children (Basel) 2021; 9 (1): 3. DOI: 10.3390/children9010003
64. Shieh M, Giannini JA, Combs SA et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits triggered by COVID-19: a case report. CEN Case Rep 2022: 1–6. DOI: 10.1007/s13730-022-00687-1
65. Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases. Pediatr Nephrol 2021; 36 (4): 1019–23. DOI: 10.1007/s00467-021-04944-w
66. Izci Duran T, Turkmen E, Dilek M et al. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021; 41 (8): 1523–9. DOI: 10.1007/s00296-021-04914-3
67. Uppal NN, Kello N, Shah HH et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5 (11): 2079–83. DOI: 10.1016/j.ekir.2020.08.012
68. Sethi S, D'Costa MR, Hermann SM et al. Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney Int Rep 2021; 6 (4): 1170–3. DOI: 10.1016/j.ekir.2021.02.002
69. Guo W, Tan PH, Baikunje S. Membranous nephropathy in a patient with COVID-19 infection. J Nephrol 2022; 35 (1): 351–5. DOI: 10.1007/s40620-021-01165-0
70. Yasri S, Wiwanitkit V. COVID-19-induced de novo nephritic syndrome.Rev Assoc Med Bras (1992) 2021; 67 (1): 6. DOI: 10.1590/ 1806-9282.67.01.20200982
71. Sakthiswary R, Chuah HY, Chiang KS et al. COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. Lupus 2021; 30 (12): 1946–54. DOI: 10.1177/09612033211045057
72. Morello W, Vianello FA, Proverbio E et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2021: 1–8. DOI: 10.1007/s00467-021-05330-2
73. Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton) 2022; 27 (1): 5–6. DOI: 10.1111/nep.14013
74. Tan HZ, Tan RY, Choo JCJ et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021; 100 (2): 469–71. DOI: 10.1016/j.kint.2021.05.009
75. Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int 2021; 100 (5): 959–65. DOI: 10.1016/j.kint.2021.09.002
76. Klomjit N, Alexander MP, Fervenza FC et al. COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep 2021; 6 (12): 2969–78. DOI: 10.1016/j.ekir.2021.09.008
77. Schaubschlager T, Rajora N, Diep S et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center. Clin Nephrol 2022. DOI: 10.5414/CN110794
78. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021; 100 (1): 238. DOI: 10.1016/j.kint.2021.04.024
79. Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int 2021; 100 (4): 944–5. DOI: 10.1016/j.kint.2021.07.020
80. Hanna C, Herrera Hernandez LP et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 202; 100 (3): 705–6. DOI: 10.1016/j.kint.2021.06.032
81. Lim CC, Choo J, Tan CS. COVID-19 Vaccination in Immunoglobulin A Nephropathy. Am J Kidney Dis 2021; 78 (4): 617. DOI: 10.1053/ j.ajkd.2021.07.001
82. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021; 100 (2): 473–4. DOI: 10.1016/j.kint.2021.05.017
83. Dube GK, Benvenuto LJ, Batal I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine. Kidney Int Rep 2021; 6 (12): 3087–9. DOI: 10.1016/j.ekir.2021.08.012
84. Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. Front Immunol 2021; 12: 762006. DOI: 10.3389/fimmu.2021. 762006
85. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78 (4): 611–3. DOI: 10.1053/j.ajkd.2021.06.016
86. Roy S, Kunaparaju S, Koduri NM et al. COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis. Case Rep Nephrol 2021; 2021: 3737751. DOI: 10.1155/2021/3737751
87. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report Am J Kidney Dis 2021; 78 (4): 607–10. DOI: 10.1053/j.ajkd.2021.06.008
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii (15-ia versiia ot 22.02.2022). Moscow, 2022. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]
2. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9 (1):727–32. DOI: 10.1080/22221751.2020.1746199
3. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14 (2): 185–92. DOI: 10.1007/ s11684-020-0754-0
4. Wang M, Xiong H, Chen H et al. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis (Basel). 2021 Mar; 7 (2): 100–10. DOI: 10.1159/000512683
5. Томилина Н.А., Фролова Н.Ф., Артюхина Л.Ю. и др. COVID-19: связь с патологией почек. Обзор литературы. Нефрология и диализ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id= 46215426
[Tomilina N.A., Frolova N.F., Artiukhina L.Iu. et al. COVID-19: sviaz' s patologiei pochek. Obzor literatury. Nefrologiia i dializ. 2021; 2: 147–59. https://www.elibrary.ru/item.asp?id=46215426 (in Rus-sian).]
6. Павлов В.Н., Тарасенко А.И., Папоян А.О. и др. Острое повреждение почек в патогенезе коронавирусной инфекции. Урология. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119
[Pavlov V.N., Tarasenko A.I., Papoian A.O. et al. Ostroe povrezhdenie pochek v patogeneze koronavirusnoi infektsii. Urologiia. 2021; 2: 116–9. DOI: 10.18565/urology.2021.2.116-119 (in Russian).]
7. Демяшкин Г.А., Мингазов А.М., Каприна Е.А. и др. Молекулярно-генетические изменения ткани почек пациентов с COVID-19. Исследования и практика в медицине. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4
[Demiashkin G.A., Mingazov A.M., Kaprina E.A. et al. Molekuliarno-geneticheskie izmeneniia tkani pochek patsientov s COVID-19. Issledovaniia i praktika v meditsine. 2021; 8 (3): 45–51. DOI: 10.17709/2410-1893-2021-8-3-4 (in Russian).]
8. Ouyang L, Gong Y, Zhu Y, Gong J. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am J Emerg Med 2021; 43: 149–57. DOI: 10.1016/j.ajem.2020 08.089
9. Острое повреждение почек (ОПП). Клинические рекомендации. М., 2020. https://rusnephrology.org/wp-content/uploads/2020/12/ AKI_final.pdf
[Ostroe povrezhdenie pochek (OPP). Klinicheskie rekomendatsii. Moscow, 2020. https://rusnephrology.org/wp-content/uploads/ 2020/12/AKI_final.pdf (in Russian).]
10. Pecly IMD, Azevedo RB, Muxfeldt ES et al. A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. J Bras Nefrol 2021; 43 (4): 551–71. DOI: 10.1590/2175-8239-JBN-2020-0204
11. Yang XH, Sun RH, Chen DC. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Zhonghua Yi Xue Za Zhi 2020; 100 (16): 1205–8. DOI: 10.3760/cma.j.cn112137-20200229-00520
12. Ng JH, Bijol V, Sparks MA et al. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis 2020; 27 (5): 365–76. DOI: 10.1053/j.ackd.2020.09.003
13. Menon T, Sharma R, Kataria S et al. The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cureus 2021; 13 (3): e13894. DOI: 10.7759/cureus.13894
14. Chan KW, Yu KY, Lee PW et al. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021; 8: 678200. DOI: 10.3389/fmed.2021.678200
15. Oliveira CB, Lima CAD, Vajgel G et al. High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. J Clin Pathol 2021; 74 (12): 796–803. DOI: 10.1136/jclinpath-2020-207023
16. Alenezi FK, Almeshari MA, Mahida R et al. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis. Ren Fail 2021; 43 (1): 1621–33. DOI: 10.1080/0886022X.2021.2011747
17. Raina R, Mahajan ZA, Vasistha P et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif 2021: 1–14. DOI: 10.1159/000514940
18. Santos RPD, Lordani TVA, Peres LAB, Carvalho ARDS. Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.09.002
19. Cai X, Wu G, Zhang J, Yang L. Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8: 719472. DOI: 10.3389/fmed.2021.719472
20. Чеботарева Н.В., Бернс С.А., Мясников А.Л. и др. Частота, факторы риска и прогностическое значение острого повреждения почек у госпитализированных больных c COVID-19: ретроспективное когортное исследование. Клиническая фармакология и терапия. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35
[Chebotareva N.V., Berns S.A., Miasnikov A.L. et al. Chastota, faktory riska i prognosticheskoe znachenie ostrogo povrezhdeniia pochek u gospitalizirovannykh bol'nykh c COVID-19: retrospektivnoe kogortnoe issledovanie. Klinicheskaia farmakologiia i terapiia. 2021; 1: 30–5. DOI: 10.32756/0869-5490-2021-1-30-35 (in Russian).]
21. Chan VW, Chiu PK, Yee CH et al. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol 2021; 39 (9): 3127–38. DOI: 10.1007/s00345-020-03246-4
22. Громова Г.Г., Верижникова Л.Н., Жбанова Н.В. и др. Повреждение почек при новой коронавирусной инфекции COVID-19. Клиническая нефрология. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22
[Gromova G.G., Verizhnikova L.N., Zhbanova N.V. et al. Povrezhdenie pochek pri novoi koronavirusnoi infektsii COVID-19. Klinicheskaia nefrologiia. 2021; 3: 17–22. DOI: 10.18565/nephrology.2021.3.17-22 (in Russian).]
23. Cai R, Zhang J, Zhu Y et al. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol 2021; 53 (8): 1623–9. DOI: 10.1007/s11255-020-02740-3
24. Menon T, Gandhi SAQ, Tariq W et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. Cureus 2021; 13 (4): e14279. DOI: 10.7759/cureus.14279
25. Lin YC, Lai TS, Lin SL et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021; 12: 2040622321998860. DOI: 10.1177/2040622321998860
26. Chung EYM, Palmer SC, Natale P et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis 2021; 78 (6): 804–15. DOI: 10.1053/j.ajkd. 2021.07.003
27. Singh J, Malik P, Patel N et al. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med 2022; 22 (1): 125–35. DOI: 10.1007/s10238-021-00715-x
28. Nopsopon T, Kittrakulrat J, Takkavatakarn K et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis. PLoS Negl Trop Dis 2021; 15 (6): e0009156. DOI: 10.1371/journal.pntd.0009156
29. Wang F, Ao G, Wang Y et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail 2021; 43 (1): 1394–407. DOI: 10.1080/0886022X. 2021.1986408
30. Сивков А.В., Корякин А.В., Синягин А.А. и др. Мочеполовая система и COVID-19: некоторые аспекты. Экспериментальная и клиническая урология. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23
[Sivkov A.V., Koriakin A.V., Siniagin A.A. et al. Mochepolovaia sistema i COVID-19: nekotorye aspekty. Eksperimental'naia i klinicheskaia urologiia. 2020; 2: 18–23. DOI: 10.29188/2222-8543-2020-12-2-18-23 (in Russian).]
31. Heldwein FL, Loeb S, Wroclawski ML et al. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. Eur Urol Focus 2020; 6 (5): 1070–85. DOI: 10.1016/j.euf.2020.05.020
32. Лаухтина Е.А., Шпикина А.Д., Тараткин М.С. и др. Обзор рекомендаций европейской ассоциации урологов по ведению урологических пациентов в период пандемии COVID-19. Вопросы урологии и андрологии. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59
[Laukhtina E.A., Shpikina A.D., Taratkin M.S. et al. Obzor rekomendatsii evropeiskoi assotsiatsii urologov po vedeniiu urologicheskikh patsientov v period pandemii COVID-19. Voprosy urologii i andrologii. 2020; 1: 52–9. DOI: 10.20953/2307-6631-2020-1-52-59 (in Russian).]
33. Малхасян В.А., Касян Г.Р., Ходырева Л.А. и др. Оказание стационарной помощи пациентам урологического профиля в условиях пандемии коронавирусной инфекции COVID-19. Экспериментальная и клиническая урология. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11
[Malkhasian V.A., Kasian G.R., Khodyreva L.A. et al. Okazanie statsionarnoi pomoshchi patsientam urologicheskogo profilia v usloviiakh pandemii koronavirusnoi infektsii COVID-19. Eksperimental'naia i klinicheskaia urologiia. 2020; 1: 4–11. DOI: 10.29188/2222-8543-2020-12-1-4-11 (in Russian).]
34. Mumm JN, Osterman A, Ruzicka M et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? Eur Urol 2020; 78 (4): 624–8. DOI: 10.1016/j.eururo.2020.05.013
35. Lamb LE, Dhar N, Timar R et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses 2020; 145: 110375. DOI: 10.1016/j.mehy. 2020.110375
36. Dhar N, Dhar S, Timar R et al. De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. J Clin Med Res 2020; 12 (10): 681–2. DOI: 10.14740/jocmr4294
37. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных синдромов и симптомов при заболеваниях почек и мочевых путей. М.: Практическая медицина, 2019. https://www. elibrary.ru/item.asp?id=47503998
[Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh sindromov i simptomov pri zabolevaniiakh pochek i mochevykh putei. Moscow: Prakticheskaia meditsina, 2019. https://www.elibrary. ru/item.asp?id=47503998 (in Russian).]
38. Трухан Д.И., Юренев Г.Л., Макушин Д.Г., Чусова Н.А. Симптомы нижних мочевых путей: дифференциальный диагноз на этапе оказания первичной медико-санитарной помощи. Справочник поликлинического врача. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801
[Trukhan D.I., Iurenev G.L., Makushin D.G., Chusova N.A. Simptomy nizhnikh mochevykh putei: differentsial'nyi diagnoz na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Spravochnik poliklinicheskogo vracha. 2019; 3: 23–8. https://www.elibrary.ru/ item.asp?id=41351801 (in Russian).]
39. Kaya Y, Kaya C, Kartal T et al. Could LUTS be early symptoms of COVID-19. Int J Clin Pract 2021; 75 (3): e13850. DOI: 10.1111/ ijcp.13850
40. Bernikov AN, Kupriyanov AA, Stroganov RV et al. Lower urinary tract symptoms and COVID-19. Urologiia 2021; 5: 78–83. https://pubmed.ncbi.nlm.nih.gov/35165599/
41. Lamb LE, Timar R, Wills M et al. Long COVID and COVID-19-associated cystitis (CAC). Int Urol Nephrol 2022; 54 (1): 17–21. DOI: 10.1007/s11255-021-03030-2
42. Pourfridoni M, Pajokh M, Seyedi F. Bladder and bowel incontinence in COVID-19. J Med Virol 2021; 93 (5): 2609–10. DOI: 10.1002/ jmv.26849
43. Araujo MP, Brito LGO, Pochini AC et al. Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19 Quarantine and its Relationship with Training Level: An Observational Study. Rev Bras Ginecol Obstet 2021; 43 (11): 847–52. DOI: 10.1055/s-0041-1739463
44. Борисов В.В. Опасности COVID-нейроинфекции и ее урологических осложнений, возможные пути преодоления (клиническая лекция). Клинический разбор в общей медицине. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078
[Borisov V.V. Opasnosti COVID-neiroinfektsii i ee urologicheskikh oslozhnenii, vozmozhnye puti preodoleniia (klinicheskaia lektsiia). Klinicheskii razbor v obshchei meditsine. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078 (in Russian).]
45. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103
[Trukhan D.I., Chuianova Iu.S., Makushin D.G. Problema nederzhaniia mochi skvoz' prizmu komorbidnosti. Klinicheskii razbor v obshchei meditsine. 2021; 9: 11–23. DOI: 10.47407/kr2021.2.9.00103 (in Russian).]
46. Silva AB, Freschi G, Carrera RV et al. COVID-19 pandemic impact on clinical outcomes of patients with obstructive pyelonephritis. Int Urol Nephrol 2021; 53 (4): 627–33. DOI: 10.1007/s11255-020-02708-3
47. Borgmann H, Struck JP, Mattigk A et al. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Urol Int 2021; 105 (3–4): 199–205. DOI: 10.1159/000513458
48. Krol BC, Hemal AK, Fenu EM et al. A rare case of emphysematous pyelonephritis caused by Candida parapsilosis and Finegoldia magna complicated by medical care avoidance. CEN Case Rep 2021; 10 (1): 111–4. DOI: 10.1007/s13730-020-00531-4
49. Cao BL, Brewer O, Cross AR. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep 2022; 15 (2): e245779. DOI: 10.1136/bcr-2021-245779
50. Djafari AA, Hojjati SA, Rahnama H et al. First report of concurrent mixed germs induced destructive emphysematous pyelonephritis and emphysematous endophthalmitis in the patient with COVID-19. Urol Case Rep 2022; 40: 101908. DOI: 10.1016/j.eucr.2021.101908
51. Boukhannous I, El Moudane A, Chennoufi M et al. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Coexistence of Emphysematous Pyelonephritis and Cystitis in a Patient with COVID-19 Complicated with Spontaneous Pneumomediastinum. Case Rep Infect Dis 2021; 2021: 3115644. DOI: 10.1155/2021/3115644
52. Castellani D, Ragonese M, Di Rosa M et al. An Italian multicenter analysis of emergency admissions and treatment of upper tract urolithiasis during the lockdown and reopening phases of the COVID-19 pandemic: Are we ready for a second wave of the outbreak? Int J Urol 2021; 28 (9): 950–4. DOI: 10.1111/iju.14612
53. Nourian A, Uppaluri C, Chen M et al. Comparison of Management and Outcomes of Symptomatic Urolithiasis during the COVID-19 Pandemic to a Comparative Cohort. Urology 2022: S0090-4295(22) 00064-4. DOI: 10.1016/j.urology.2022.01.019
54. Anderson S, McNicholas D, Murphy C et al. The impact of COVID-19 on acute urinary stone presentations: a single-centre experience. Ir J Med Sci 2022; 191 (1): 45–9. DOI: 10.1007/s11845-021-02562-x
55. Abdel Raheem A, Alowidah I, Soliman M, et al. Urolithiasis treatment options during COVID-19 pandemic: review of current recommendations and triage systems. Afr J Urol 2020; 26 (1): 75. DOI: 10.1186/s12301-020-00085-y
56. Cepeda M, Budía A, Pérez-Fentes D et al. Strategies and recommendations for urolithiasis treatment and follow-up in COVID-19 pandemia. Arch Esp Urol 2020; 73 (5): 438–46. https://pubmed. ncbi.nlm.nih.gov/32538815/
57. Heijkoop B, Galiabovitch E, York N, Webb D. Consensus of multiple national guidelines: agreed strategies for initial stone management during COVID-19. World J Urol 2021; 39 (9): 3161–74. DOI: 10.1007/ s00345-020-03491-7
58. Scotland K, Tailly T, Chew BH et al. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol 2022. DOI: 10.1089/end.2021.0477
59. Demirdogen SO, Cinislioglu AE, Cinislioglu N et al. Treatment management of COVID-19 positive patients with renal colic secondary to distal ureteral stone. Int J Clin Pract 2021; 75 (5): e13976. DOI: 10.1111/ijcp.13976
60. Moran SM, Barbour S, Dipchand C et al.; CSN COVID-19 Rapid Response Team. Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis 2020; 7: 2054358120968955. DOI: 10.1177/205435 8120968955
61. May RM, Cassol C, Hannoudi A et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021; 100 (6): 1303–15. DOI: 10.1016/j.kint.2021.07.015
62. Waldman M, Soler MJ, García-Carro C et al. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int 2021; 99 (1): 227–37. DOI: 10.1016/j.kint.2020.10.032
63. Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review. Children (Basel) 2021; 9 (1): 3. DOI: 10.3390/children9010003
64. Shieh M, Giannini JA, Combs SA et al. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits triggered by COVID-19: a case report. CEN Case Rep 2022: 1–6. DOI: 10.1007/s13730-022-00687-1
65. Basiratnia M, Derakhshan D, Yeganeh BS, Derakhshan A. Acute necrotizing glomerulonephritis associated with COVID-19 infection: report of two pediatric cases. Pediatr Nephrol 2021; 36 (4): 1019–23. DOI: 10.1007/s00467-021-04944-w
66. Izci Duran T, Turkmen E, Dilek M et al. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021; 41 (8): 1523–9. DOI: 10.1007/s00296-021-04914-3
67. Uppal NN, Kello N, Shah HH et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5 (11): 2079–83. DOI: 10.1016/j.ekir.2020.08.012
68. Sethi S, D'Costa MR, Hermann SM et al. Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney Int Rep 2021; 6 (4): 1170–3. DOI: 10.1016/j.ekir.2021.02.002
69. Guo W, Tan PH, Baikunje S. Membranous nephropathy in a patient with COVID-19 infection. J Nephrol 2022; 35 (1): 351–5. DOI: 10.1007/s40620-021-01165-0
70. Yasri S, Wiwanitkit V. COVID-19-induced de novo nephritic syndrome.Rev Assoc Med Bras (1992) 2021; 67 (1): 6. DOI: 10.1590/ 1806-9282.67.01.20200982
71. Sakthiswary R, Chuah HY, Chiang KS et al. COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. Lupus 2021; 30 (12): 1946–54. DOI: 10.1177/09612033211045057
72. Morello W, Vianello FA, Proverbio E et al. COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatr Nephrol 2021: 1–8. DOI: 10.1007/s00467-021-05330-2
73. Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton) 2022; 27 (1): 5–6. DOI: 10.1111/nep.14013
74. Tan HZ, Tan RY, Choo JCJ et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021; 100 (2): 469–71. DOI: 10.1016/j.kint.2021.05.009
75. Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int 2021; 100 (5): 959–65. DOI: 10.1016/j.kint.2021.09.002
76. Klomjit N, Alexander MP, Fervenza FC et al. COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep 2021; 6 (12): 2969–78. DOI: 10.1016/j.ekir.2021.09.008
77. Schaubschlager T, Rajora N, Diep S et al. De novo or recurrent glomerulonephritis and acute tubulointerstitial nephritis after COVID-19 vaccination: A report of six cases from a single center. Clin Nephrol 2022. DOI: 10.5414/CN110794
78. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021; 100 (1): 238. DOI: 10.1016/j.kint.2021.04.024
79. Plasse R, Nee R, Gao S, Olson S. Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination. Kidney Int 2021; 100 (4): 944–5. DOI: 10.1016/j.kint.2021.07.020
80. Hanna C, Herrera Hernandez LP et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int 202; 100 (3): 705–6. DOI: 10.1016/j.kint.2021.06.032
81. Lim CC, Choo J, Tan CS. COVID-19 Vaccination in Immunoglobulin A Nephropathy. Am J Kidney Dis 2021; 78 (4): 617. DOI: 10.1053/ j.ajkd.2021.07.001
82. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021; 100 (2): 473–4. DOI: 10.1016/j.kint.2021.05.017
83. Dube GK, Benvenuto LJ, Batal I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine. Kidney Int Rep 2021; 6 (12): 3087–9. DOI: 10.1016/j.ekir.2021.08.012
84. Hakroush S, Tampe B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination. Front Immunol 2021; 12: 762006. DOI: 10.3389/fimmu.2021. 762006
85. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78 (4): 611–3. DOI: 10.1053/j.ajkd.2021.06.016
86. Roy S, Kunaparaju S, Koduri NM et al. COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis. Case Rep Nephrol 2021; 2021: 3737751. DOI: 10.1155/2021/3737751
87. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report Am J Kidney Dis 2021; 78 (4): 607–10. DOI: 10.1053/j.ajkd.2021.06.008
Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-01-2022/novaya_koronavirusnaya_infektsiya_covid_19_i_zabolevaniya_patologicheskie_sostoyaniya_pochek_i_moche/
Для цитирования:Трухан Д.И. Новая коронавирусная инфекция (COVID-19) и заболевания / патологические состояния почек и мочевых путей. Клинический разбор в общей медицине. 2022; 1: 6–15. DOI: 10.47407/kr2022.3.1.00111
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)